A Phase 3 interventional study of somatropine in Growth Hormone Deficiency, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2009-02-12.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Primary objective:
to evaluate the practicability and acceptability of STYLOMAX®, a new injection device for MAXOMAT®, in children, for 1 year.
171 studies on the registry are indexed under Dwarfism, Pituitary; 25 are open to participants now.
This study's enrollment of 12 is below the median of 69 across 127 interventional studies indexed under Dwarfism, Pituitary.
Browse Dwarfism, Pituitary studies →Sanofi is the lead sponsor of 1,548 studies on the registry; 88 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 122 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: somatropine
subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
practicability/acceptability of the Stylomax pen
Time frame: at each visit
tolerability : pain (evaluation on pain scale)
Time frame: at each visit
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.